Evidence map›Paper›PMID 35600849›Full record

ArticleFrontiers in pharmacology2022

Semi-Synthetic Analogues of Cryptolepine as a Potential Source of Sustainable Drugs for the Treatment of Malaria, Human African Trypanosomiasis, and Cancer.

Yabalu Z Abacha, Arnold Donkor Forkuo, Stephen Y Gbedema, Nimisha Mittal, Sabine Ottilie, Frances Rocamora, Elizabeth A Winzeler, Donelly A van Schalkwyk, John M Kelly, Martin C Taylor and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 5 countries.

Yabalu Z AbachaSchool of Pharmacy and Medical Sciences, University of Bradford, Bradford, United Kingdom.
Arnold Donkor ForkuoDepartment of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana.
Stephen Y GbedemaDepartment of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, KNUST, Kumasi, Ghana.
Nimisha MittalMalaria Drug Accelerator (MalDA) Consortium, School of Medicine, University of California, San Diego, La Jolla, CA, United States.
Sabine OttilieMalaria Drug Accelerator (MalDA) Consortium, School of Medicine, University of California, San Diego, La Jolla, CA, United States.
Frances RocamoraMalaria Drug Accelerator (MalDA) Consortium, School of Medicine, University of California, San Diego, La Jolla, CA, United States.
Elizabeth A WinzelerMalaria Drug Accelerator (MalDA) Consortium, School of Medicine, University of California, San Diego, La Jolla, CA, United States.
Donelly A van SchalkwykDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
John M KellyDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Martin C TaylorDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Janette ReaderDepartment of Biochemistry, Genetics and Microbiology, Faculty of Natural and Agricultural Sciences, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, South Africa.
Lyn-Marie BirkholtzDepartment of Biochemistry, Genetics and Microbiology, Faculty of Natural and Agricultural Sciences, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, South Africa.
David R LisgartenBiomolecular Research Group, School of Psychology and Life Sciences, Canterbury Christ Church University, Canterbury, United Kingdom.
Jeremy K CockcroftDepartment of Chemistry, Christopher Ingold Laboratories, University College London, London, United Kingdom.
John N LisgartenSchool of Science, University of Greenwich, Chatham, United Kingdom.
Rex A PalmerDepartment of Crystallography, Biochemical Sciences, Birkbeck College, University of London, London, United Kingdom.
Rosemary C TalbertBiomolecular Research Group, School of Psychology and Life Sciences, Canterbury Christ Church University, Canterbury, United Kingdom.
Steven D ShnyderSchool of Pharmacy and Medical Sciences, Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom.
Colin W WrightSchool of Pharmacy and Medical Sciences, University of Bradford, Bradford, United Kingdom.
University of California, San Diego · USLondon School of Hygiene & Tropical Medicine · GBUniversity of Bradford · GBCanterbury Christ Church University · GBKwame Nkrumah University of Science and Technology · GHUniversity of Pretoria · ZABirkbeck, University of London · GBUniversity College London · GBUniversity of Greenwich · GB

Funding

Medical Research Council MR/T015969/1
6 · The paper itself

Abstract

The prospect of eradicating malaria continues to be challenging in the face of increasing parasite resistance to antimalarial drugs so that novel antimalarials active against asexual, sexual, and liver-stage malaria parasites are urgently needed. In addition, new antimalarials need to be affordable and available to those most in need and, bearing in mind climate change, should ideally be sustainable. The West African climbing shrub

Indexed as

halogenation of cryptolepineovarian cancerPlasmodium falciparumPlasmodium knowlesisustainable pharmaceuticalsTrypanosoma brucei

Identifiers

PMID35600849
PMCPMC9119314
OpenAlexW4224712439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.